Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus

Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures

Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. 

Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy

The first study of certolizumab pegol in combination with methotrexate in DMARD-naïve early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. 

Brivaracetam, a selective high affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. 

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.